Accelerated regression of brain metastases in patients receiving whole brain radiation and the topoisomerase II inhibitor, lucanthone

John D. Del Rowe, Jacqueline A. Bello, Robin Mitnick, Brij Sood, Christopher Filippi, Justin Moran, Katherine Freeman, Frances Mendez, Robert Bases

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

Purpose: To determine if lucanthone crossed the blood-brain barrier in experimental animals; and to determine accelerated tumor regression of human brain metastases treated jointly with lucanthone and whole brain radiation. Methods and Materials: The organ distribution of 3H lucanthone in mice and 125I lucanthone in rats was determined to learn if lucanthone crossed the blood-brain barrier. Size determinations were made of patients' brain metastases from magnetic resonance images or by computed tomography before and after treatment with 30 Gy whole brain radiation alone or with lucanthone. Results: The time course of lucanthone's distribution in brain was identical to that in muscle and heart after intraperitoneal or intravenous administration in experimental animals. Lucanthone, therefore, readily crossed the blood-brain barrier in experimental animals. Conclusion: Compared with radiation alone, the tumor regression in patients with brain metastases treated with lucanthone and radiation was accelerated, approaching significance using a permutation test at p = 0.0536.

Original languageEnglish (US)
Pages (from-to)89-93
Number of pages5
JournalInternational Journal of Radiation Oncology Biology Physics
Volume43
Issue number1
DOIs
StatePublished - Jan 1999

Fingerprint

Lucanthone
Topoisomerase II Inhibitors
metastasis
inhibitors
brain
regression analysis
Radiation
blood-brain barrier
Neoplasm Metastasis
Brain
radiation
animals
Blood-Brain Barrier
tumors
size determination
permutations
muscles
organs
rats
mice

Keywords

  • Blood-brain barrier
  • Lucanthone
  • Topoisomerase II

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Radiation

Cite this

Accelerated regression of brain metastases in patients receiving whole brain radiation and the topoisomerase II inhibitor, lucanthone. / Del Rowe, John D.; Bello, Jacqueline A.; Mitnick, Robin; Sood, Brij; Filippi, Christopher; Moran, Justin; Freeman, Katherine; Mendez, Frances; Bases, Robert.

In: International Journal of Radiation Oncology Biology Physics, Vol. 43, No. 1, 01.1999, p. 89-93.

Research output: Contribution to journalArticle

Del Rowe, John D. ; Bello, Jacqueline A. ; Mitnick, Robin ; Sood, Brij ; Filippi, Christopher ; Moran, Justin ; Freeman, Katherine ; Mendez, Frances ; Bases, Robert. / Accelerated regression of brain metastases in patients receiving whole brain radiation and the topoisomerase II inhibitor, lucanthone. In: International Journal of Radiation Oncology Biology Physics. 1999 ; Vol. 43, No. 1. pp. 89-93.
@article{1d785be7c1b3480fbdb3ed63ff5ad908,
title = "Accelerated regression of brain metastases in patients receiving whole brain radiation and the topoisomerase II inhibitor, lucanthone",
abstract = "Purpose: To determine if lucanthone crossed the blood-brain barrier in experimental animals; and to determine accelerated tumor regression of human brain metastases treated jointly with lucanthone and whole brain radiation. Methods and Materials: The organ distribution of 3H lucanthone in mice and 125I lucanthone in rats was determined to learn if lucanthone crossed the blood-brain barrier. Size determinations were made of patients' brain metastases from magnetic resonance images or by computed tomography before and after treatment with 30 Gy whole brain radiation alone or with lucanthone. Results: The time course of lucanthone's distribution in brain was identical to that in muscle and heart after intraperitoneal or intravenous administration in experimental animals. Lucanthone, therefore, readily crossed the blood-brain barrier in experimental animals. Conclusion: Compared with radiation alone, the tumor regression in patients with brain metastases treated with lucanthone and radiation was accelerated, approaching significance using a permutation test at p = 0.0536.",
keywords = "Blood-brain barrier, Lucanthone, Topoisomerase II",
author = "{Del Rowe}, {John D.} and Bello, {Jacqueline A.} and Robin Mitnick and Brij Sood and Christopher Filippi and Justin Moran and Katherine Freeman and Frances Mendez and Robert Bases",
year = "1999",
month = "1",
doi = "10.1016/S0360-3016(98)00374-5",
language = "English (US)",
volume = "43",
pages = "89--93",
journal = "International Journal of Radiation Oncology Biology Physics",
issn = "0360-3016",
publisher = "Elsevier Inc.",
number = "1",

}

TY - JOUR

T1 - Accelerated regression of brain metastases in patients receiving whole brain radiation and the topoisomerase II inhibitor, lucanthone

AU - Del Rowe, John D.

AU - Bello, Jacqueline A.

AU - Mitnick, Robin

AU - Sood, Brij

AU - Filippi, Christopher

AU - Moran, Justin

AU - Freeman, Katherine

AU - Mendez, Frances

AU - Bases, Robert

PY - 1999/1

Y1 - 1999/1

N2 - Purpose: To determine if lucanthone crossed the blood-brain barrier in experimental animals; and to determine accelerated tumor regression of human brain metastases treated jointly with lucanthone and whole brain radiation. Methods and Materials: The organ distribution of 3H lucanthone in mice and 125I lucanthone in rats was determined to learn if lucanthone crossed the blood-brain barrier. Size determinations were made of patients' brain metastases from magnetic resonance images or by computed tomography before and after treatment with 30 Gy whole brain radiation alone or with lucanthone. Results: The time course of lucanthone's distribution in brain was identical to that in muscle and heart after intraperitoneal or intravenous administration in experimental animals. Lucanthone, therefore, readily crossed the blood-brain barrier in experimental animals. Conclusion: Compared with radiation alone, the tumor regression in patients with brain metastases treated with lucanthone and radiation was accelerated, approaching significance using a permutation test at p = 0.0536.

AB - Purpose: To determine if lucanthone crossed the blood-brain barrier in experimental animals; and to determine accelerated tumor regression of human brain metastases treated jointly with lucanthone and whole brain radiation. Methods and Materials: The organ distribution of 3H lucanthone in mice and 125I lucanthone in rats was determined to learn if lucanthone crossed the blood-brain barrier. Size determinations were made of patients' brain metastases from magnetic resonance images or by computed tomography before and after treatment with 30 Gy whole brain radiation alone or with lucanthone. Results: The time course of lucanthone's distribution in brain was identical to that in muscle and heart after intraperitoneal or intravenous administration in experimental animals. Lucanthone, therefore, readily crossed the blood-brain barrier in experimental animals. Conclusion: Compared with radiation alone, the tumor regression in patients with brain metastases treated with lucanthone and radiation was accelerated, approaching significance using a permutation test at p = 0.0536.

KW - Blood-brain barrier

KW - Lucanthone

KW - Topoisomerase II

UR - http://www.scopus.com/inward/record.url?scp=0032943024&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032943024&partnerID=8YFLogxK

U2 - 10.1016/S0360-3016(98)00374-5

DO - 10.1016/S0360-3016(98)00374-5

M3 - Article

VL - 43

SP - 89

EP - 93

JO - International Journal of Radiation Oncology Biology Physics

JF - International Journal of Radiation Oncology Biology Physics

SN - 0360-3016

IS - 1

ER -